Published in J Hypertens on November 01, 2001
Take Control of Your Blood Pressure (TCYB) study: a multifactorial tailored behavioral and educational intervention for achieving blood pressure control. Patient Educ Couns (2007) 1.69
Salt handling and hypertension. J Clin Invest (2004) 1.38
Linkage disequilibrium and haplotype diversity in the genes of the renin-angiotensin system: findings from the family blood pressure program. Genome Res (2003) 1.13
Public health genomics: translating obesity genomics research into population health benefits. Obesity (Silver Spring) (2008) 0.90
Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system. Am J Hypertens (2010) 0.88
Beta2-adrenergic receptor genotype affects the renin-angiotensin-aldosterone system response to the Dietary Approaches to Stop Hypertension (DASH) dietary pattern. Am J Clin Nutr (2010) 0.88
Blood Pressure-Lowering Mechanisms of the DASH Dietary Pattern. J Nutr Metab (2012) 0.84
Genetics, ancestry, and hypertension: implications for targeted antihypertensive therapies. Curr Hypertens Rep (2014) 0.83
Renin gene polymorphisms in bangladeshi hypertensive population. J Genomics (2014) 0.81
Characteristics associated with informed consent for genetic studies in the ACCORD trial. Contemp Clin Trials (2013) 0.78
Genetic architecture of complex traits predisposing to nephropathy: hypertension. Semin Nephrol (2010) 0.76
Difficulties in achieving arterial hypertension control. Maedica (Buchar) (2011) 0.75
Open-label randomized trial of titrated disease management for patients with hypertension: Study design and baseline sample characteristics. Contemp Clin Trials (2016) 0.75
Genetics of cardiovascular disease. Clin Cases Miner Bone Metab (2008) 0.75
Strategies to improve detection of hypertension genes. J Nutrigenet Nutrigenomics (2011) 0.75
Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med (2001) 20.18
A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med (1997) 19.93
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell (1999) 9.74
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13
Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med (2001) 5.90
Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr (1999) 5.12
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation (2000) 4.80
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 3.69
Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med (2001) 3.56
Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev (1979) 3.36
Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA (1997) 3.27
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism (2001) 3.25
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr (2001) 3.12
Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension (2000) 3.01
The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med (2001) 2.81
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
Definition, measurement, and classification of the syndromes of obesity. Int J Obes (1978) 2.69
Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med (1991) 2.68
Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men. Am J Epidemiol (1992) 2.68
Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst (1994) 2.68
The relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes Relat Metab Disord (2002) 2.64
Complications of obesity. Ann Intern Med (1985) 2.55
Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med (1999) 2.51
Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure. N Engl J Med (1990) 2.37
Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet (2001) 2.35
Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res (1999) 2.30
Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet (1989) 2.28
The relation between dietary intake and adipose tissue composition of selected fatty acids in US women. Am J Clin Nutr (1998) 2.24
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Assessment of energy intake underreporting by doubly labeled water and observations on reported nutrient intakes in children. J Am Diet Assoc (1998) 2.18
Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res (1973) 2.17
Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer. J Natl Cancer Inst (1993) 2.15
Quantitative trait loci affecting peak bone mineral density in mice. J Bone Miner Res (1998) 2.08
The Zucker-fatty rat: a review. Fed Proc (1977) 2.04
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med (1996) 2.03
Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol (2001) 2.03
Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. JAMA (1999) 2.02
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes (Lond) (2008) 1.99
Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res (2001) 1.96
Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia (2011) 1.93
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke (2000) 1.90
Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab (1997) 1.88
Cardiovascular disease in women. Circulation (1993) 1.87
Effect of caloric restriction on energy expenditure in obese patients. Lancet (1969) 1.86
DASH (Dietary Approaches to Stop Hypertension) diet is effective treatment for stage 1 isolated systolic hypertension. Hypertension (2001) 1.83
Fatty acid composition of subcutaneous adipose tissue and diet in postmenopausal US women. Am J Clin Nutr (1991) 1.78
A short history of beverages and how our body treats them. Obes Rev (2008) 1.77
Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest (1980) 1.76
Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA (2001) 1.75
A prospective study of egg consumption and risk of cardiovascular disease in men and women. JAMA (1999) 1.74
beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ Res (1997) 1.73
Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Rapid Early Action for Coronary Treatment (REACT) Study Group. Am Heart J (1999) 1.73
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol (1998) 1.67
Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). NHP Investigative Team. Hypertension (1995) 1.62
Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr (2000) 1.62
Genetically transmitted obesity in rodents. Physiol Rev (1971) 1.61
Overweight is risking fate. Definition, classification, prevalence, and risks. Ann N Y Acad Sci (1987) 1.61
Fat and carbohydrate balances during adaptation to a high-fat. Am J Clin Nutr (2000) 1.60
Plasma lipids and lipoproteins in vegetarians and controls. N Engl J Med (1975) 1.59
Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem (1989) 1.58
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res (1999) 1.58
Chewing the fat--how much and what kind? N Engl J Med (1991) 1.57
Suppression of appetite by bile acids. Lancet (1968) 1.56
Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects. Diabetes (1992) 1.56
Prevalence of cardiovascular risk factors in South Korean adults: results from the Korea Medical Insurance Corporation (KMIC) Study. Ann Epidemiol (1998) 1.55
A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin Cardiol (1999) 1.52
Overview of the Activity Counseling Trial (ACT) intervention for promoting physical activity in primary health care settings. Activity Counseling Trial Research Group. Med Sci Sports Exerc (1998) 1.51
Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer (1999) 1.50
Skinfold thickness measurements in obese subjects. Am J Clin Nutr (1990) 1.45
Chamber for indirect calorimetry with accurate measurement and time discrimination of metabolic plateaus of over 20 min. Med Biol Eng Comput (2003) 1.44
Synthesis of 3-ketoacyl-CoA thiolase of rat liver peroxisomes on free polyribosomes as a larger precursor. Induction of thiolase mRNA activity by clofibrate. Biochem J (1985) 1.43
Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. J Hum Hypertens (2005) 1.43
Dietary fat affects obesity rate. Am J Clin Nutr (1999) 1.42
Does vegetable oil attenuate the beneficial effects of fish oil in reducing risk factors for cardiovascular disease? Am J Clin Nutr (1997) 1.42
The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc (1999) 1.40
Blood pressure in vegetarians. Am J Epidemiol (1974) 1.40
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia (2009) 1.39